NCT06161246已完成4 期
An Open-label, Randomized, Split-face, Controlled Study on Pain Management With Injection of Botulinum Toxin for Glabellar Line Correction
适应症
干预措施
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- Galderma R&D
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- Visual Analogue Scale
研究概览
简要总结
This is an open-label, single-center, randomized, split-face, controlled study to assess the effect of comfort intervention on pain during treatment injection compared against non-comfort intervention.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 64 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Adult subjects aged 18-65 years
- •Females or males
- •Having any Fitzpatrick skin types I-VI
- •Any races and ethnicities
- •Having any self-assessed pain tolerance, with a minimum of 5 subjects in each category (low, medium, and high pain tolerance)
- •Subject with intent to undergo correction of the glabellar lines (frown lines between the eyebrows)
- •Subject with moderate-to-severe glabellar lines as assessed by investigator using Glabellar Line Severity Scale (GLSS).
- •Subject with no history of aesthetic injection, i.e., botulinum toxin, collagen, hyaluronic acid, calcium hydroxyapatite, poly L-lactic acid or permanent materials.
- •Subject with healthy immune systems
- •Subject willing to abstain from any other facial plastic surgical or cosmetic procedure(s) during the duration of the study.
- •For female subjects of childbearing potential, she must not be pregnant, breastfeeding or planning pregnancy during the course of the study. Subjects must be willing to take a urine pregnancy test (UPT) prior to all treatment injections.
- •Ability of giving consent for participation in the study
- •Agreement to adhere to the procedures and requirements of the study and to report to the site on the day(s) and at the time(s) scheduled for the assessments
排除标准
- •Pregnant, breastfeeding, or planning pregnancy during the course of the study, confirmed by UPT.
- •Current smokers or consumer nicotine (e.g., cigarettes, e-cigarettes, vaping device with pre-filled pods, vapor tank or mod, chewing tobacco)
- •History of allergy or hypersensitivity to botulinum toxin type A, human albumin, lactose, or cow's milk protein
- •Subject with signs and symptoms of eyelid or brow ptosis, inability to substantially lessen glabellar lines by physically spreading them apart, or history or presence of facial nerve palsy, as judged by the Investigator.
- •Previous or present multiple allergies or severe allergies, such as manifested by anaphylaxis or angioedema, or family history of these conditions.
- •Previous aesthetic treatment in the face with any of the following injection prior to the baseline visit:
- •Botulinum toxin
- •Collagen, hyaluronic acid
- •Calcium hydroxylapatite, poly L-lactic acid, fat or permanent materials (non-biodegradable)
- •Previous treatment/procedure in the face in the previous 2-4 weeks that, in the Investigator's opinion, would interfere with the study injections and/or study assessments or exposed the study subject to undue risk by study participation, or planning to undergo any of these procedures affecting the treatment area at any time during the study e.g.,
- •Resurfacing (laser, photo modulation, light, radiofrequency, ultrasound, chemical peel, dermabrasion, or other ablative/non-ablative procedures)
- •Needling or mesotherapy
- •Cryotherapy
- •Presence of any disease or lesions near or on the glabellar region, e.g.,
- •Inflammation, active, or chronic infection in or near the treatment area
- •Psoriasis, eczema, rosacea, atopic dermatitis, herpes zoster/herpes simplex, and acanthosis
- •Scars or deformities
- •History of bleeding disorders or treatment with anticoagulants or inhibitors of platelet aggregation (e.g., aspirin or other non-steroidal anti-inflammatory drugs), omega 3, or vitamin E within 14 days before treatment. Omega 3 and vitamin E are acceptable only as part of a standard multivitamin formulation.
- •Planning on having surgeries and/or invasive medical procedures during the course of the study
研究组 & 干预措施
Treatment Group
Experimental
Subjects will be treated for correction of glabellar lines with Dysport and comfort intervention on one side and Dysport only on the other side depending on pre-determined randomization. Subjects will complete the study assessments and end the study.
干预措施: Vibrating Beauty Bar (Device)
结局指标
主要结局
Visual Analogue Scale
时间窗: Baseline
Visual Analogue Scale is a 11-point psychometric scale that specifies the level of pain. Subject will be shown a photo of a VAS and verbally report a pain score between 0 and 10, which will be captured by a clinic staff. A score of 0 corresponds to no pain felt and a score of 10 corresponds to very high pain.
次要结局
- Self-assessment questionnaire(Baseline)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
2 期
Topical Ruxolitinib for Face and Neck Vitiligo of Adult Chinese Patients Refractory to Topical TacrolimusVitiligoNCT06719024Hospital Authority, Hong Kong20
已完成
3 期
Study of Secukinumab Compared to Fumaderm® in Adults With Moderate to Severe Psoriasis.PsoriasisNCT02474082Novartis Pharmaceuticals202
已完成
2 期
Short-course Radiotherapy Followed by Tislelizumab + CapeOX in the Treatment for Locally Advanced Rectal CancerLocally Advanced Rectal CancerNCT05086627Hebei Medical University Fourth Hospital118
Unknown
2 期
The Efficacy of Intravenous Immunoglobulin Therapy for Severe 2019-nCoV Infected Pneumonia2019-nCoVNCT04261426Peking Union Medical College Hospital80
Unknown
早期 1 期
Safety and Efficacy of HO/02/02 20µg vs. SoC (Aloe Vera) to Reduce Radiation DermatitisBreast CancerNCT01923220HealOr90